EUCTR2009-015791-94-FI进行中（未招募）不适用
A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 70 years and older. - ZOSTER-022
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 14,512
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects who the investigator believes will comply with the requirements of the protocol (e.g. completion of the diary cards/questionnaires, return for follow-up visits, have regular contact to allow evaluation during the study);
- •Written informed consent obtained from the subject;
- •A male or female aged 70 years or older at the time of the first vaccination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 14512
排除标准
- •Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period;
- •Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product (pharmaceutical product or device);
- •Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., malignancy, HIV infection) or immunosuppressive/cytotoxic therapy (e.g., medications used during cancer chemotherapy, organ transplantation or to treat autoimmune disorders);
- •History of HZ;
- •Previous vaccination against varicella or HZ (either registered product or participation in a previous vaccine study, and including previous vaccination with childhood varicella vaccine);
- •History of allergic disease or reactions likely to be exacerbated by any component of the vaccine. Additionally, consider allergic reactions to other material or equipment related to study participation (such as materials that may possibly contain latex -gloves, syringes, etc). Please note, the vaccine and vials in this study do not contain latex;
- •Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study (e.g., life-threatening disease likely to limit survival to less than 4 years);
- •Receipt of immunoglobulins and/or any blood products within the 90 days preceding the first dose of study vaccine or planned administration during the study period;
- •Administration or planned administration of any other immunizations within 30 days before the first or second study vaccination or scheduled within 30 days after study vaccination. However, licensed non-replicating vaccines (i.e., inactivated and subunit vaccines, including inactivated and subunit influenza vaccines for seasonal or pandemic flu, with or without adjuvant) may be administered up to 8 days prior to each dose and/or at least 14 days after any dose of study vaccine;
- •Any other condition (e.g., extensive psoriasis, chronic pain syndrome, cognitive impairment, severe hearing loss) that, in the opinion of the investigator, might interfere with the evaluations required by the study;
- •Acute disease and/or fever at the time of enrolment; Fever is defined as temperature = 37.5°C (99.5°F) on oral, axillary or tympanic setting, or = 38.0°C (100.4°F) on rectal setting. The preferred route for recording temperature in this study will be oral. Subjects with a minor illness (such as mild diarrhoea, mild upper respiratory infection) without fever may, be enrolled at the discretion of the investigator.
- •Chronic administration (defined as more than 15 consecutive days) of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose. For corticosteroids, this will mean prednisone < 20 mg/day, or equivalent, is allowed. Inhaled and topical steroids are allowed.
研究者
相似试验
进行中（未招募）
不适用
Study to evaluate GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged =70 years.Primary immunization of subjects = 70 YOA against Herpes Zoster (HZ). The study population includes males and females without severely immunocompromising conditions in the age ranges 70-79 YOA and = 80 YOA.MedDRA version: 17.0Level: LLTClassification code 10019982Term: Herpes zoster NOSSystem Organ Class: 100000004862EUCTR2009-015791-94-CZGlaxoSmithKline Biologicals14,512
进行中（未招募）
不适用
Study to evaluate GSK Biologicals' Herpes Zoster vaccine GSK1437173A in adults aged >= 50 years.Primary immunization of subjects = 50 years of age (YOA) against Herpes Zoster (HZ). The study population includes males and females without severely immunocompromising conditions in the age ranges 50-59 YOA, 60-69 YOA, 70-79 YOA and = 80 YOA.MedDRA version: 18.0Level: PTClassification code 10019974Term: Herpes zosterSystem Organ Class: 10021881 - Infections and infestationsEUCTR2008-000367-42-DEGlaxoSmithKline Biologicals15,980
进行中（未招募）
1 期
A phase III, randomized, observer-blind, placebo-controlled, multicentre, clinical vaccination trial to assess the prophylactic efficacy, safety, and immunogenicity of GSK Biologicals’ gE/AS01B vaccine when administered intramuscularly on a 0, 2-month schedule in adults aged 50 years and older. - ZOSTER-006EUCTR2008-000367-42-FRGlaxoSmithKline Biologicals15,429
进行中（未招募）
不适用
Study to evaluate GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged =70 years.Primary immunization of subjects = 70 YOA against Herpes Zoster (HZ). The study population includes males and females without severely immunocompromising conditions in the age ranges 70-79 YOA and = 80 YOA.MedDRA version: 17.0Level: LLTClassification code 10019982Term: Herpes zoster NOSSystem Organ Class: 100000004862EUCTR2009-015791-94-GBGlaxoSmithKline Biologicals14,512
进行中（未招募）
不适用
Study to evaluate GSK Biologicals’ Herpes Zoster vaccine GSK1437173A in adults aged >= 50 years.Primary immunization of subjects = 50 years of age (YOA) against Herpes Zoster (HZ). The study population includes males and females without severely immunocompromising conditions in the age ranges 50-59 YOA, 60-69 YOA, 70-79 YOA and = 80 YOA.MedDRA version: 17.0Level: LLTClassification code 10019982Term: Herpes zoster NOSSystem Organ Class: 100000004862EUCTR2008-000367-42-EEGlaxoSmithKline Biologicals15,980